An official website of the United States government
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Trial Status: closed to accrual
This study will evaluate the safety, tolerability, drug levels, molecular effects, and
clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have
a KRAS G12C mutation.
Inclusion Criteria
Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation
Unresectable or metastatic disease
Standard treatment is not available or patient declines; first-line treatment for NSCLC for certain cohorts
Adequate organ function
Exclusion Criteria
History of intestinal disease or major gastric surgery or inability to swallow oral medications
Other active cancer
Additional locations may be listed on ClinicalTrials.gov for NCT03785249.
